Everett Vokes

Project Optimus for Radiation Therapy–Drug Combinations: Moving Beyond the Maximum Tolerated Dose

Alastair Greystoke, Sarah Brown, Anthony Chalmers, Jamie Dean et autres

gb, fr, ie, nl, us (code pays fourni par la source)

Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Wenji Guo, Noura J. Choudhury, Rachel Hartnett, Theodore Karrison et autres

us (code pays fourni par la source)

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Onkar V. Khullar et autres

Importance: Preoperative and perioperative nivolumab improve event-free survival in resectable non-small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown. Objective: To determine whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non-small cell …

us, gb, my (code pays fourni par la source)

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538

Jeffrey A. Bogart, Xiaofei Wang, Gregory Masters, Ritsuko Komaki et autres

us (code pays fourni par la source)

OA01.03: Uncovering Hidden Risk: The Role of Family History in Lung Cancer Among Women and Low-Exposure Smokers

Sulin Wu, Alessandra Esposito, Christine Bestvina, Matthew Platta et autres

MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial

Alexander T. Pearson, J. Muzaffar, Kedar Kirtane, Emily Bellile et autres

Preclinical studies have evaluated murine double minue 2 (MDM2) inhibitors as a treatment for adenoid cystic carcinoma (ACC), but clinical trials are lacking. This phase I trial (NCT03781986) assesses the safety and antitumor activity of an oral MDM2 inhibitor, alrizomadlin (APG-115), +/- …

us (code pays fourni par la source)

MA18.04 Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC) : Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538

Michael K Farris, Michael D. Mix, Xinkai Wang, Nathan R. Foster et autres

us (code pays fourni par la source)

PL03.06 Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])

N.K. Altorki, X. Wang, D. Kozono, Christean Watt et autres

us, ca (code pays fourni par la source)